Peptide "cycles" for joint repair

"Cycles" are a community convention imported from anabolic-steroid culture: 4–12 week runs of one or more injectable peptides — most commonly BPC-157 plus TB-500, sometimes with GHK-Cu or oral "bioregulators" — followed by time off. This entry appraises the practice, not any single compound; each compound has its own entry.

The rationale for cycling

No published rationale exists for cycling these compounds: no tolerance, receptor-downregulation, or accumulation data exist in humans for any of them. The stack logic — "BPC for local healing, TB-500 systemically" — is forum reasoning, not literature. For the practice of cycling or stacking, the human evidence is none whatsoever. The only published human combination study is a retrospective case series in which four patients received intra-articular BPC-157 plus thymosin β4 — uncontrolled and uninterpretable. And the one controlled animal test of the community's favorite stack found the combination added nothing over either peptide alone.

Component by component

• Pentosan polysulfate — promising. The outlier, and not actually a peptide: one placebo-controlled human RCT with symptom benefit, a sponsor-run phase 2 biomarker RCT, and a pivotal phase 3 reading out around Q1 2027. It is also the one compound a reader cannot buy as a legitimate human injectable for OA — which is precisely the point: the best-evidenced agent is in trials, not in vials.
• BPC-157 — preclinical. Consistent rodent tendon, ligament, and bone healing, nearly all from one lab network; zero human RCTs; the sole independent head-to-head found it short of significance on load to failure and total histology, and never different from TB-500.
• TB-500 / Tβ4 — preclinical, with a harm signal. Positive rat ligament and tendon data, but the most cartilage-specific finding is increased matrix-degrading MMP-9 in chondrocytes.
• GHK-Cu — preclinical. Real dermal wound-healing biology; its single joint study showed a transient benefit gone by 12 weeks.
• Sigumir — anecdotal. One uncontrolled, confounded human series from the originating institute; vendor citations largely unverifiable.
• Cartalax — anecdotal. A few institute-run cell-culture papers in non-cartilage cells; no human data at all.

The inverted pyramid

The evidence pyramid here stands on its point: the compounds easiest to buy have the least evidence, and the compound with real RCT data is unavailable outside trials and veterinary medicine. Stacking multiplies unknowns — interactions between these agents have been tested exactly once, in rats, with no additive benefit. And publication bias is a live concern: the BPC-157 literature's uniform positivity from a small author network is itself a warning sign.

Regulatory reality and safety

BPC-157 and TB-500 sit outside FDA approval entirely — BPC-157 was flagged in FDA's 503A Category 2 safety-concern process in 2023 — and both are WADA-prohibited at all times, with real sanctions on record. Community protocol numbers trace to forums and vendors, not trials; products are sold as "research chemicals" specifically to evade drug regulation, with identity and purity unverified. This site does not provide sourcing or dosing advice for unapproved compounds.

The safety summary is "unknown risk, taken on faith": human safety data across all the gray-market compounds in this section total a two-person, two-day IV pilot and small uncontrolled series. Pro-angiogenic peptides carry unstudied theoretical malignancy concerns; TB-500 carries a cartilage-catabolism signal; injecting unregulated products carries sterility and dosing risks; athletes risk 4-year bans. Absence of reported harm in tiny series is not evidence of safety.

The orthopaedic literature now says much of this itself. A 2026 review in the American Academy of Orthopaedic Surgeons' open-access journal, written to give surgeons a framework for patients who arrive already using these compounds, describes the evidence as dominated by animal models, small cohorts and case series with very limited randomised trials, and says clinical use should be framed as exploratory and hypothesis-generating rather than standard of care. It documents the problem this section calls "community protocol numbers": the same peptide given at doses spanning a fivefold range across regimens with no consensus on a threshold. On sourcing it names what the unregulated market delivers — inconsistent dosing, label discrepancies and endotoxin contamination that can provoke systemic inflammation — and sets the bar it would accept: certificates of analysis for each lot, third-party sterility and endotoxin testing, and current good manufacturing practice. It closes with a minimum reporting standard for any future study, from peptide sequence and lot number through purity, sterility, dose, schedule and safety monitoring.

What could move this section

One event on the horizon: the pentosan phase 3 readout expected Q1 2027 — the only thing that could move any of this past preclinical. Beyond that, watch for any gray-market peptide entering a registered human musculoskeletal trial, or independent replication of the BPC-157 rodent corpus.